Relation Expression of Eestrogen Reseptor and Ki67 in Invasive Ductal Carcinoma Breast Cancer

Christian B, Daniel Sampepajung, Prihantono Prihantono, Berti Nelwan, Burhanuddin Bahar


Estrogen are potent mitogenic stimuli that share important properties in the control of cellular proliferation. Increased expression and/or activity of estrogen reseptor (ER) result in aberrant activation of downstream signaling pathways including cAMP/PKA, MAPK/ERK and PI3K/AKT. The importance of estrogen and as a signaling axis in cancer development, progression and metastasis is highlighted by its effects on cancer cells, notably proliferation. But, all mechanism of this proliferation action ER and Ki67 not complete clear yet. The study aims to explore the coupling between the signaling cascades of estrogen receptors to celular proliferation (Ki67). This research used an exploration analitik with cross sectional design, 59 specimen pathologi were explore with Immunohistochemia (IHC) examine to asses expression of Estrogen reseptor and Ki67 in invasif ductal breast cancer. To asses corelation beetwen ER and Ki67 with Chi-Square Test. Result found that the IHC examation show that propotion ER. : 35/ 55 (63 %), Ki67 :32/55 ( 58 %) in invasive ductal breast cancer. Correlated beetwen ER and Ki67 expression no signi?cant p>0.05 in invasif ductal breast cancer. In conclution, ER does not play a signi?cant role in celluler proliferation in Invasive breast cancer.


Expression ER and Ki67; Carcinoma breast cancer.

Full Text:



Desantis C, Ma, J., Bryan, L. & Jemal, A. . Breast cancer statistics, 2013. , . CA: a cancer journal for clinicians. 2014.;64, .52-62.

Aaltonen KE, Rosendahl AH, Olsson H, Malmstrm P, Hartman L, Fern M. Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. BMC cancer. 2014;14(1):794.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005;55(2):74-108.

Murray S, Briasoulis, E., Linardou, H., Bafaloukos, D. & Papadimitriou, C. . Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. . Cancer treatment reviews, . 2012. ;38, :890-903.

Yaghjyan L, Colditz GA. Estrogens in the breast tissue: a systematic review. Cancer Causes & Control. 2011;22(4):529-40.

Zhang X, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast cancer research and treatment. 2013;137(3):883-92.

Marino M, Acconcia F, Bresciani F, Weisz A, Trentalance A. Distinct nongenomic signal transduction pathways controlled by 17?-estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 cells. Molecular biology of the cell. 2002;13(10):3720-9.

Kenny Fs, Hui R, Musgrove Ea, Gee Jm, Blamey Rw, Nicholson Ri, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clinical cancer research. 1999;5(8):2069-76.

Jakowlew SB, Breathnach R, Jeltsch J-M, Masiakowski P, Chambon P. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic acids research. 1984;12(6):2861-78.

Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. The Journal of Immunology. 1984;133(4):1710-5.

Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer research. 2005;25(3A):1719-23.

Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011;9(1):131.

Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, et al. Sex Hormone Levels and Risks of Estrogen ReceptorNegative and Estrogen ReceptorPositive Breast Cancers. Journal of the National Cancer Institute. 2011;103(7):562-70.

Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocrine-related cancer. 2010;17(1):125-34.

Kim J-Y, Han W, Moon H-G, Ahn SK, Kim J, Lee JW, et al. Prognostic effect of preoperative Serum estradiol level in postmenopausal breast cancer. BMC cancer. 2013;13(1):503.

Shapochka D, Zaletok S, Gnidyuk M. Relationship between NF-?B, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Experimental oncology. 2012;34(4):358-63.

Pietilinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V, Syrjnen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. Journal of cancer research and clinical oncology. 1996;122(11):687-92.

Huang P, Liu L-X. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-? Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis. Asian Pacific Journal of Cancer Prevention. 2015;16(2):823-9.

Bouzubar N, Walker K, Griffiths K, Ellis I, Elston C, Robertson J, et al. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. British journal of cancer. 1989;59(6):943.

Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi M, Marco B, et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer research. 1995;16(5B):3105-10.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC cancer. 2011;11(1):486.

Ingolf JB, Russalina M, Simona M, Julia R, Gilda S, Bohle RM, et al. Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? BioMed research international. 2014;2014:628217.

Inwald E, Klinkhammer-Schalke M, Hofstdter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast cancer research and treatment. 2013;139(2):539-52.

de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. British journal of cancer. 2007;96(10):1504-13.

Dowsett M, Nielsen TO, AHern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute. 2011.

Luporsi E, Andr F, Spyratos F, Martin P-M, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast cancer research and treatment. 2012;132(3):895-915.

DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Annals of oncology. 2011;22(3):582-7.

Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. Journal of clinical oncology. 2005;23(28):7212-20.

Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. Breast. 2014;23(1):69-75.

Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, Van de Vijver M. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British journal of Cancer. 2003;88(3):406-12.

Honkoop A, Van Diest P, De Jong J, Linn S, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. British journal of cancer. 1998;77(4):621.

McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642-4.


  • There are currently no refbacks.





About IJSBAR | Privacy PolicyTerms & Conditions | Contact Us | DisclaimerFAQs 

IJSBAR is published by (GSSRR).